Jason W. D. Hearn

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

Jason W. D. Hearn

Aug 24, 2024, 12:41 | Insight

Nima Sharifi: HSD3B1 and outcomes with ADT+enzalutamide in ARCHES

Nima Sharifi, Scientific Director, Desai Sethi Urology Institute, at University of Miami Miller School of…

Aug 23, 2024, 14:37 | Insight

Yüksel Ürün: Enzalutamide boosts OS and rPFS in mHSPC patients regardless of HSD3B1 genotype

Yüksel Ürün shared a paper by Nima Sharifi et al. on X: "Enzalutamide boosts OS…

All: 2 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023